“VAGABOND Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students” aims to create a multidisciplinary and multi-sectoral program to validate new therapeutic interventions in paediatric cancer. The program is funded by the European Commission under the Horizon 2020 programme (Marie Sklodowska-Curie Actions Innovative Training Network) and offers 15 fully funded PhD positions. The consortium is coordinated by the Princess Máxima Center for Pediatric Oncology and consists of 12 academic and 6 non-academic partners from 8 European countries.
15 PhD projects
The research projects are focused on genetic, epigenetic and immunological targets and hosted by 11 academic and non-academic institutes located in 8 European Countries.
The overall goal of VAGABOND is to create an efficient approach to validate new target-drug combinations in paediatric cancer. VAGABOND will gain knowledge in 8 difficult to treat paediatric cancers to overcome the limitation of their rare nature by efficient knowledge and data-sharing between beneficiaries and partners. VAGABOND will exchange expertise in the 4 steps of the proof of concept pipeline for pre-clinical drug development of genetic, epigenetic and immunologic targets. VAGABOND will train a new generation of young scientist to translate science to therapeutic applications fuelling innovation and entrepreneurship.
The PhD students will get equipped with all necessary qualities and skills to make a significant difference in pre-clinical drug development. They will get the opportunity to work with and gain experience from world-class scientist from leading European industrial partners and academic institutes in the area of pediatric oncology. Read more about the individual research projects here.